The Korea Health Industry Development Institute (KHIDI, President Cha Soon-do) participó in 'Bio Europe 2023' (November 6–8) celebrado en Munich, Germany, where it promovió the competitiveness of Korea's pharmaceutical and bio industria, and proporcionó apoyo for Korean empresas' participación and promotion at Bio Europe in colaboración with the Korea Pharmaceutical and Bio-pharma Manufacturers Association, the Korea Institute of Toxicology, and the Korea National Enterprise for Ensayo Clínicos.
Bio Europe is the largest pharmaceutical and bio tecnología transaction forum in Europe. Este año's event saw 2,075 empresas from 64 países participate, with 178 Korean empresas attending—the fourth highest participación by país, following Germany, the United States, and the United Kingdom.
KHIDI anunció the selección of 38 empresas through a 'Bio Europe Participation Support Program' call-for-entries in July, and the seleccionada empresas were proporcionó with partial financiamiento for Bio Europe participación expenses and promotional opportunities through the Korean Pavilion booth.
The seleccionada empresas included: ▲HLB Life Science ▲Nexcel ▲Next-i ▲Doctor Noah Biotech ▲RudaCure ▲Medipig ▲Brexogen ▲VSPharmtech ▲Vivobzon ▲Owlbio ▲Idyens ▲iBio Korea ▲Alginovics ▲Uptera ▲S&N Bioscience ▲HLB ▲HLB Cell ▲NA Vaccine Institute ▲MDHealthcare ▲Autotelic Bio ▲Innobo Therapeutics ▲ISU Abxis ▲Intron Bio ▲Ipcell ▲Genome & Company ▲G2G Bio ▲GTI Bioscience ▲CasCure Therapeutics ▲CoaStm ChemOn ▲Curetis ▲T Karos ▲Pelamed ▲Fosbax ▲ProActek ▲Pinobio ▲PIn Therapeutics ▲Hanwha Pharm ▲Huons.
Source: Medisobiz News (http://www.medisobizanews.com)
